Can someone assist me with a brief statement as to where we are with fragile X ....
For example, would the Phase 1 Safety Trial for Rett Syndrome be applicable to the Fragile X community?
Have we any results for efficacy of treatment against Fragile X?
The reason I ask is that the commercial arrangements soon to be negotiated will be for much higher numbers of dollars if "big pharma" thinks that Trofinetide is the answer for both afflictions.
Cheers
Ann: Neuren completes Phase 2 trial in pediatric Rett syndrome, page-28
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.70 |
Change
-0.220(1.58%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.94 | $13.96 | $13.50 | $3.626M | 264.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 836 | $13.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.71 | 322 | 16 |
View Market Depth
| Last trade - 14.33pm 06/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |